Skip to content

The effectiveness of oral Cicaglucal on wound healing and pruritus management in patients with Epidermolysis bullosa

Investigating the effectiveness of oral Cicaglucal on wound healing and pruritus management in patients with Epidermolysis bullosa

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150825023753N22
Enrollment
15
Registered
2024-01-09
Start date
2024-01-15
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis bullosa. Epidermolysis bullosa

Interventions

Intervention group: Cicaglucal capsule is administered once a day for up to one month. In cases where patients are unable to take the medicine due to difficulty in swallowing the capsule, the capsule

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with epidermolysis bullosa who have been confirmed by a dermatologist Consent of the patient and the patient's parents to participate in the study The patient complains of skin sores and itching

Exclusion criteria

Exclusion criteria: Positive history of drug hypersensitivity Patients who have problems with swallowing any type of medication

Design outcomes

Primary

MeasureTime frame
The number of wounds on the surface of the patient's body. Timepoint: Before drug administration and one month after drug administration. Method of measurement: Count the number of wounds.;Severity of itching. Timepoint: Before drug administration and one month after drug administration. Method of measurement: Dynamic Pruritus Score (DPS).

Secondary

MeasureTime frame
Overall improvement rate from the patient's point of view. Timepoint: One month after taking the drug. Method of measurement: Patient global impression of improvement(PGI-I).;Overall improvement rate from the physician's point of view. Timepoint: One month after taking the drug. Method of measurement: Impression of improvement (CGI-I).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Mahdi Parvizi

Shiraz University of Medical Sciences

mmparvizi@gmail.com+98 71 3212 5592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026